Michael Schoof,Bryan Faust,Reuben A. Saunders,Smriti Sangwan,Veronica Rezelj,Nick Hoppe,Morgane Boone,Christian B. Billesbølle,Cristina Puchades,Caleigh M. Azumaya,Huong T. Kratochvil,Marcell Zimanyi,Ishan Deshpande,Jiahao Liang,Sasha Dickinson,Henry C. Nguyen,Cynthia M. Chio,Gregory E. Merz,Michael C. Thompson,Devan Diwanji,Kaitlin Schaefer,Aditya A. Anand,Niv Dobzinski,Beth Shoshana Zha,Camille R. Simoneau,Kristoffer Leon,Kris M. White,Un Seng Chio,Meghna Gupta,Mingliang Jin,Fei Li,Yanxin Liu,Kaihua Zhang,David Bulkley,Ming Sun,Amber M. Smith,Alexandrea N. Rizo,Frank Moss,Axel F. Brilot,Sergei Pourmal,Raphael Trenker,Thomas Pospiech,Sayan Gupta,Benjamin Barsi-Rhyne,Vladislav Belyy,Andrew W. Barile-Hill,Silke Nock,Yuwei Liu,Nevan J. Krogan,Corie Y. Ralston,Danielle L. Swaney,Adolfo García-Sastre,Melanie Ott,Marco Vignuzzi,Peter Walter,Aashish Manglik,Caleigh M. Azumaya,Cristina Puchades,Ming Sun,Julian R. Braxton,Axel F. Brilot,Meghna Gupta,Fei Li,Kyle E. Lopez,Arthur Melo,Gregory E. Merz,Frank Moss,Joana Paulino,Thomas H. Pospiech,Sergei Pourmal,Alexandrea N. Rizo,Amber M. Smith,Paul V. Thomas,Feng Wang,Zanlin Yu,Miles Sasha Dickinson,Henry C. Nguyen,Daniel Asarnow,Melody G. Campbell,Cynthia M. Chio,Un Seng Chio,Devan Diwanji,Bryan Faust,Meghna Gupta,Nick Hoppe,Mingliang Jin,Junrui Li,Yanxin Liu,Gregory E. Merz,Smriti Sangwan,Tsz Kin Martin Tsui,Raphael Trenker,Donovan Trinidad,Eric Tse,Kaihua Zhang,Fengbo Zhou,Nadia Herrera,Huong T. Kratochvil,Ursula Schulze-Gahmen,Michael C. Thompson,Iris D. Young,Justin Biel,Ishan Deshpande,Xi Liu,Christian Bache Billesbølle,Carlos Nowotny,Amber M. Smith,Jianhua Zhao,Alisa Bowen,Nick Hoppe,Yen-Li Li,Phuong Nguyen,Mali Safari,Kaitlin Schaefer,Natalie Whitis,Michelle Moritz,Tristan W. Owens,Amy Diallo,Kate Kim,Jessica K. Peters,Erron W. Titus,Jenny Chen,Loan Doan,Sebastian Flores,Victor L. Lam,Yang Li,Megan Lo,Aye C. Thwin,Stephanie Wankowicz,Yang Zhang,David Bulkley,Arceli Joves,Almarie Joves,Liam McKay,Mariano Tabios,Oren S. Rosenberg,Kliment A. Verba,David A. Agard,Yifan Cheng,James S. Fraser,Adam Frost,Natalia Jura,Tanja Kortemme,Nevan J. Krogan,Aashish Manglik,Daniel R. Southworth,Robert M. Stroud,

Abstract:Nanobodies that neutralize Monoclonal antibodies that bind to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show therapeutic promise but must be produced in mammalian cells and need to be delivered intravenously. By contrast, single-domain antibodies called nanobodies can be produced in bacteria or yeast, and their stability may enable aerosol delivery. Two papers now report nanobodies that bind tightly to spike and efficiently neutralize SARS-CoV-2 in cells. Schoof et al. screened a yeast surface display of synthetic nanobodies and Xiang et al. screened anti-spike nanobodies produced by a llama. Both groups identified highly potent nanobodies that lock the spike protein in an inactive conformation. Multivalent constructs of selected nanobodies achieved even more potent neutralization. Science , this issue p. 1473 , p. 1479

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape

Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern

Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2

An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike

Nanobody engineering for SARS-CoV-2 neutralization and detection

Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering

A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization

A Novel Nanobody Broadly Neutralizes SARS‐CoV‐2 Via Induction of Spike Trimer Dimers Conformation

Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2

Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization

Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants

A Potent Synthetic Nanobody with Broad-Spectrum Activity Neutralizes SARS-Cov-2 Virus and Omicron Variant Through a Unique Binding Mode

Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

A potent neutralizing nanobody targeting a unique epitope on the receptor-binding domain of SARS-CoV-2 spike protein